<DOC>
	<DOCNO>NCT00367705</DOCNO>
	<brief_summary>Crohn 's disease ( CD ) childhood chronic relapse remit condition significant impact growth development . The disease characterize increase unregulated immune response . The main therapy last 30 year corticosteroid lead remission 50-80 % patient within 2-4 week . However , use steroid child limit side-effects include acne , moon-face , hirsutism , hypertension , metabolic disturbance reduce growth . Hence , pediatrician interested find alternative therapy . Therapeutic manipulation gut flora probiotic promise useful strategy several disorder include inflammation gut . The efficacy highly concentrated probiotic VSL # 3 documented maintenance prophylaxis treatment pouchitis double blind , placebo control study adult . The aim study compare probiotic therapy VSL # 3 versus placebo maintenance therapy child mild moderate CD , treat either 5-ASA , corticosteroid ( local budesonide ) , imuran/6 mercaptopurine ( MP ) , long change medication dosage make previous 12 week ( imuran/6MP ) 4 week ( corticosteroid ) .</brief_summary>
	<brief_title>VSL # 3 Treatment Children With Crohn 's Disease</brief_title>
	<detailed_description>The aim study compare probiotic therapy VSL # 3 versus placebo maintenance therapy child mild moderate CD , treat either 5-ASA , corticosteroid ( local budesonide ) , imuran/6MP , long change medication dosage make previous 12 week ( imuran/6MP ) 4 week ( corticosteroid ) . The primary goal compare ability maintain remission decrease disease activity two study group . Data collect 16 week period regard safety tolerability VSL # 3 , well data change stool composition microflora upon treatment . The follow continue 6 month monthly telephone questionnaire clinical visit 6 month . Study Design : The study multinational , double-blind , randomize control study ( Munich , Paris , Rotterdam , Porto , Brussels , London , Warsaw , Chicago , Toronto , Boston , New York , Baltimore , Cleveland , Karachi Jerusalem ) . The study include 300 child last least 16 week . These child receive either 1-2 packet accord weight ; sachet contain 900 billion bacteria/day VSL # 3 identical placebo , 16 week . All patient participate study continue regular medication throughout study period . According Pediatric Crohn 's Disease Activity Index ( PCDAI ) patient assess clinically regular interval stool culture ( include lactobacillus , bifidobacteria Strep salivarius ) well stool calprotectin treatment .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Children age 6 18 year 2 . Previous diagnosis Crohn 's disease newly diagnose symptom least three month recruitment study.The diagnosis CD establish : 1. history symptom disease 2. endoscopy/histology radiology negative stool culture . 3 . Written inform consent parent 4 . PCDAI &gt; 12.5 &lt; 30 5 . Treatment 5ASA , budesonide imuran/6MP daily provide dose remain stable 4 week ( corticosteroid ) 12 week ( imuran/6MP ) prior inclusion . Children treat medication ( antiTNF antibiotic include ciprofloxacilin metronidazole ) enter study . 1 . Short bowel syndrome/ileostomy/abscess/fistula/small bowel obstruction/stenosis/stricture 2 . Imminent surgery 3 . Treatment antiTNF , systemic corticosteroid , ciprofloxacillin , metronidazole within 12 week start trial . 4 . Participation another clinical trial within last 30 day . 5 . Patients take antibiotic study . 6 . Patients take opioids , cholestyramine , ursodeoxycholic acid study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>